Extended Data Fig. 3: Enhanced immune responses in tumours with PPP2R1A mutations in the baseline and upon ICB treatment.

a-b. GSEA of PPP2R1A^mut AKT^WT versus PPP2R1A^WT AKT^WT samples in pretreatment (a) and on-treatment (b) timepoints, showing the enrichment of immune-related signatures in the former group. c. GSEA based on longitudinal comparisons of on-treatment versus pretreatment samples in the PPP2R1A-mutant group, showing the upregulated immune signatures upon ICB treatment. d-g. Longitudinal changes of the relative abundance of CD8⁺ T cells (d), activated NK cells (e), resting NK cells (f), and total NK cells (g) in all samples from the PPP2R1A-mutant and WT groups. h-i. Longitudinal changes of TCR (h) and BCR (i) richness in all samples from the PPP2R1A-mutant and WT groups. In box plots, the centre line represents the median value; the lower and upper hinges correspond to the first and third quartiles, respectively; the whiskers represent 1.5 × interquartile ranges. For panels d-i, P values were calculated using two-sided Wilcoxon rank sum tests.